What was the primary driver of revenue changes in this quarter?

The primary driver of revenue changes was the merger with Schering-Plough, which combined the operations and product portfolios of both companies, leading to a significant increase in consolidated revenues.

How did the merger with Schering-Plough impact Merck's expenses?

The merger resulted in increased expenses, particularly integration-related costs, which include severance, facility consolidations, and systems integration. Additionally, research and development expenses remain a significant investment area.

What is the company's financial position following the merger?

Merck maintained a solid cash position but also incurred a substantial amount of debt to finance the acquisition of Schering-Plough. Investors should monitor the company's debt levels and its ability to generate cash flow to service this debt.

Are there any specific product performance details mentioned in the filing?

While the filing indicates strong performance in key therapeutic areas, detailed product-by-product revenue breakdowns would typically be found in the Management's Discussion and Analysis section or subsequent earnings releases. Investors should look for commentary on the performance of flagship products from both Merck and the former Schering-Plough.

MRK 10-Q Quarterly Report Q1 FY2010 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. reported its first-quarter 2010 financial results, reflecting the integration of its merger with Schering-Plough. The company experienced a significant increase in revenues driven by the combined entity, with notable contributions from key pharmaceutical products. However, investors should note the impact of integration-related costs and ongoing research and development expenditures on profitability. The balance sheet shows a solid cash position, but also increased debt following the merger. Attention should be paid to the company's commentary on future product pipelines and the competitive landscape.

Financial Highlights

49 data points

Beta

Revenue

$11.42B

0.5% Gross Margin

Net Income

$299.00M

0.0% Net Margin

EPS (Diluted)

$0.09

Total Assets

$111.59B

Cash & Equivalents

$8.24B

Free Cash Flow

$1.37B

Financial Statements

Beta

Revenue	$11.42B
Cost of Revenue	$5.22B
Gross Profit	$6.21B
R&D Expenses	$2.05B
SG&A Expenses	$3.22B
Interest Expense	$181.00M
Net Income	$299.00M
EPS (Basic)	$0.10
EPS (Diluted)	$0.09
Shares Outstanding (Basic)	3.11B
Shares Outstanding (Diluted)	3.14B

Key Highlights

1Revenue growth driven by the merger with Schering-Plough, leading to a combined entity with a broader portfolio.
2Strong performance in key therapeutic areas, though specific product details are subject to the combined company's reporting.
3Increased operating expenses related to integration costs and continued investment in R&D.
4The company maintained a healthy cash flow from operations despite integration challenges.
5Significant debt increase on the balance sheet resulting from the acquisition financing.
6Management commentary likely addresses the strategic benefits and operational efficiencies expected from the merger.

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions